Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia

NCT00030355 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

NIH

Sponsor class

Conditions

Leukemia

Interventions

DRUG: homoharringtonine
PROCEDURE: chemotherapy

Sponsor

National Cancer Institute (NCI)